M
Meena Kadapakkam
Researcher at Stanford University
Publications - 8
Citations - 736
Meena Kadapakkam is an academic researcher from Stanford University. The author has contributed to research in topics: Chimeric antigen receptor & Poloxamer. The author has an hindex of 6, co-authored 7 publications receiving 411 citations. Previous affiliations of Meena Kadapakkam include University of Texas at Austin & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas.
Christopher Mount,Robbie G. Majzner,Shree Sundaresh,Evan Arnold,Meena Kadapakkam,Samuel T. Haile,Louai Labanieh,Esther Hulleman,Pamelyn Woo,Skyler P. Rietberg,Hannes Vogel,Michelle Monje,Crystal L. Mackall +12 more
TL;DR: It is reported that patient-derived H3-K27M-mutant glioma cell cultures exhibit uniform, high expression of the disialoganglioside GD2, thereby making these tumors susceptible to chimeric antigen receptor T cell–based immunotherapy.
Journal ArticleDOI
Tuning the Antigen Density Requirement for CAR T-cell Activity.
Robbie G. Majzner,Skyler P. Rietberg,Elena Sotillo,Rui Dong,Vipul T. Vachharajani,Louai Labanieh,June Helen Myklebust,June Helen Myklebust,Meena Kadapakkam,Evan W. Weber,Aidan Tousley,Rebecca Richards,Sabine Heitzeneder,Sang M. Nguyen,Volker Wiebking,Johanna Theruvath,Rachel C. Lynn,Peng Xu,Alexander R. Dunn,Ronald D. Vale,Crystal L. Mackall +20 more
TL;DR: It is demonstrated that CD19 CAR activity is dependent upon antigen density and the CAR construct in axicabtagene-ciloleucel (CD19-CD28z) outperforms that in tisagenlecleucel(CD19) against antigen low tumors and CARs incorporating a CD28-H/T demonstrate a more stable and efficient immunological synapse.
Journal ArticleDOI
PEGylation strategies for active targeting of PLA/PLGA nanoparticles.
Tania Betancourt,James D. Byrne,Nicole Sunaryo,Spencer W. Crowder,Meena Kadapakkam,Shefali Patel,Shelly L. Casciato,Lisa Brannon-Peppas +7 more
TL;DR: Copolymers of PLGA with PEG were determined to be more effective and versatile by polymerization of lactide and glycolide dimers onto the hydroxyl group of heterofunctional OH-PEG-COOH than by conjugation of the premade polymers with carbodiimide chemistry.
Journal ArticleDOI
Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
Liora M. Schultz,Lori Muffly,Jay Y. Spiegel,Sneha Ramakrishna,Nasheed Hossain,Christina Baggott,Bita Sahaf,Shabnum Patel,Juliana Craig,Jenny Sumin Yoon,Meena Kadapakkam,Robbie G. Majzner,Matthew J. Frank,Courtney Erickson,Anne Cunniffe Marcy,Michelle Fujimoto,Neehar Bhatia,Everett Meyer,Katherine A. Kong,Emily Egeler,Sharon Mavroukakis,Haiying Qin,Terry J. Fry,Steven A. Feldman,David B. Miklos,Crystal L. Mackall,Kara L. Davis +26 more
TL;DR: The combined single institution experience to date of pediatric and adult patients with R/R ALL treated with this novel bispecific CAR is presented and no differences in toxicities were seen across the patient age spectrum and there were no cases of treatment-related mortality within 28 days following CAR T infusion.
Journal ArticleDOI
Repurposing Drugs for Acute Myeloid Leukemia: A Worthy Cause or a Futile Pursuit?
Anna V. Wojcicki,Meena Kadapakkam,Adam Frymoyer,Norman J. Lacayo,Hee-Don Chae,Kathleen M. Sakamoto +5 more
TL;DR: This review provides an overview of previously U.S. Food and Drug Administration approved non-chemotherapy drugs under investigation for the treatment of AML and suggests several approaches to identify new therapies with fewer financial and regulatory hurdles.